PENSACOLA, FL, and PARIS, FRANCE, Nov 9, 2026 – Ametris, a Signant Health company and global provider of digital health technologies (DHTs) for clinical research, and Biosency, a Withings company specializing in predictive remote monitoring for chronic respiratory diseases, today announced a new partnership to bring objective, continuous measurement of chronic obstructive pulmonary disease (COPD) exacerbations to clinical trials. Biosency’s COPD exacerbation detection algorithm will be available through Ametris’ Connect Algorithm Marketplace, enabling studies using the ActiGraph LEAP® multisensor wearable to capture secondary or exploratory digital endpoints that characterize the occurrence, severity, and dynamics of acute exacerbations of COPD (AECOPD). Exacerbation data are delivered alongside Ametris' existing digital measures of function, sleep, cough, and other respiratory endpoints as part of the most comprehensive DHT solution in the industry for COPD and other respiratory diseases.
“The value of digital health technologies lies in their ability to transform data collected in patients' daily lives into robust clinical evidence,” said Jeremy Wyatt, CEO of Ametris. “Combining the LEAP® device with Biosency's COPD algorithms and expertise opens a promising path toward more complete exacerbation measurement while reducing burden on participants and sites.”
The partnership applies Biosency's interpretable exacerbation detection algorithm to physiological data collected with the ActiGraph LEAP® device, focusing on respiratory rate, heart rate, and oxygen saturation to characterize events using an approach aligned with the Rome proposal for the definition and severity classification of COPD exacerbations. The Biosency exacerbation algorithm was evaluated in a study (NCT04963192) published in PLOS Digital Health in May 2026: among 220 patients with COPD monitored for six months, the score anticipated physician-validated exacerbations by an average of 4.4 ± 3.1 days, with an area under the ROC curve of 0.88 and overall accuracy of 84.8%. At a threshold providing 85% specificity, sensitivity was 74%, and median adherence to the wearable was 86%.
“This algorithm has demonstrated that interpretable analysis of passively collected vital signs can anticipate and objectively characterize COPD exacerbations,” said Marie Pirotais, General Manager of Biosency. “Together with Ametris, we aim to bring this capability into clinical trials and provide sponsors with a more complete view of disease activity and treatment response.”
Exacerbation identification in clinical trials has traditionally relied heavily on health records, investigator-completed case report forms, and patient-reported outcomes. These sources are essential, but they may under-document episodes that are managed at home or in primary care and may introduce variability related to patient reporting. This partnership is designed to complement those sources with passive, continuous physiological measures collected directly from participants in their daily lives.
By combining continuous physiological data with fit-for-purpose algorithmic analysis, this platform integration helps study teams document a broader range of clinically meaningful events, grade their severity beyond simple event counts, and characterize recovery trajectories over time — enriching treatment-effect analyses, supporting the identification of responder sub-phenotypes, and facilitating real-world evidence generation.
Contact us to learn more about how this partnership can support your COPD research.
About Ametris
Founded in 2004 and formerly known as ActiGraph, Ametris is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Its end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific and operational support across the clinical trial lifecycle, from study design through submission. Ametris became a Signant Health company in May 2026, bringing wearable-derived measures together with Signant's evidence generation capabilities. Learn more: ametris.com
About Biosency
Founded in 2017 and acquired by Withings in June 2026, Biosency develops predictive medicine and remote monitoring solutions designed to improve home-based care for patients with chronic respiratory insufficiency, particularly COPD. Its Bora care® solution combines the Bora band® medical wearable, the Bora connect® platform and the proprietary BVS³ predictive score to continuously monitor cardiorespiratory parameters and identify early signs of clinical deterioration. As part of Withings, Biosency is positioned to accelerate innovation in respiratory remote monitoring and expand access to preventive, continuous care. Learn more: biosency.com
Media Contacts
Ametris: Genevieve Baley – genevieve.baley@ametris.com
Biosency: Marie Pirotais – marie.pirotais@biosency.com
Scientific Reference
Tilquin F, Le Liepvre S, Balbolia S, et al. Short-term prediction of COPD exacerbations based on wearable vital sign monitoring. PLOS Digital Health. 2026;5(5):e0001405. doi: 10.1371/journal.pdig.0001405.